206536-96-1
Chemical Structure
FNIII14
- CAS No.: 206536-96-1
- Formula:C103H163N21O35
- Molecular Weight:2255.52
SMILES: O=C(N[C@@H](CCC(O)=O)C(NC(C)C(N[C@@H](C(O)C)C(NC(C(C)CC)C(N[C@@H](C(O)C)C(NCC(NC(CC(C)C)C(NC(CCC(O)=O)C(N1[C@H](CCC1)C(NCC(NC(C(O)C)C(NC(CCC(O)=O)C(NC(CC2=CC=C(C=C2)O)C(NC(C(O)C)C(NC(C(C)CC)C(NC(CC3=CC=C(C=C3)O)C(NC(C(C)C)C(NC(C(C)CC)C(NC(C)C(NC(CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C(C(O)C)N
Biological Activity: FNIII14 is a β1-integrin inhibitory peptide. FNIII14 induces the conformational shift of β1-integrin from the active form to the inactive form, blocks integrin-mediated signaling pathways, disrupts the interaction between VLA-4 and fibronectin, inhibits the phosphorylation of FAK/Akt, suppresses cell adhesion, fibronectin fibril formation and chondrocyte proliferation, induces chondrocyte apoptosis and cartilage degeneration, upregulates the pro-apoptotic protein Bim, and binds to membrane-bound eEF1A. FNIII14 reversibly disrupts cell adhesion without reducing cell viability, accelerates adipocyte differentiation, and loosens tumor matrix architecture to enhance the permeability of nanotherapeutic agents. FNIII14 can be used in research related to neuroblastoma, pancreatic cancer, acute myeloid leukemia, colitis-associated colorectal cancer, osteoarthritis, and atherosclerosis[1][2][3][4][5][6][7][8][9][10].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FNIII14 | 96.55% | FNIII14 is a β1-integrin inhibitory peptide. FNIII14 induces the conformational shift of β1-integrin from the active form to the inactive form, blocks integrin-mediated signaling pathways, disrupts the interaction between VLA-4 and fibronectin, inhibits the phosphorylation of FAK/Akt, suppresses cell adhesion, fibronectin fibril formation and chondrocyte proliferation, induces chondrocyte apoptosis and cartilage degeneration, upregulates the pro-apoptotic protein Bim, and binds to membrane-bound eEF1A. FNIII14 reversibly disrupts cell adhesion without reducing cell viability, accelerates adipocyte differentiation, and loosens tumor matrix architecture to enhance the permeability of nanotherapeutic agents. FNIII14 can be used in research related to neuroblastoma, pancreatic cancer, acute myeloid leukemia, colitis-associated colorectal cancer, osteoarthritis, and atherosclerosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Fujita M, et al. Biofunctional Peptide FNIII14: Therapeutic Potential. Encyclopedia. 2021 Apr 8;1(2):350‑359.
- [2]. Matsunaga T, et al. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia. 2008 Feb;22(2):353-60. [Content Brief]
- [3]. Itagaki K, et al. Exposure of the cryptic de-adhesive site FNIII14 in fibronectin molecule and its binding to membrane-type eEF1A induce migration and invasion of cancer cells via β1-integrin inactivation. American journal of cancer research. 2020;10(11):3990-4004. [Content Brief]
- [4]. Fujita M, et al. Involvement of Integrin-Activating Peptides Derived from Tenascin-C in Cancer Aggression and New Anticancer Strategy Using the Fibronectin-Derived Integrin-Inactivating Peptide. Molecules (Basel, Switzerland). 2020 Jul 16;25(14):3239. [Content Brief]
- [5]. Nishimura F, et al. Fibronectin Peptide FNIII14 Enhances Progressive Cartilage Degeneration in Osteoarthritis by Inducing Chondrocyte Apoptosis. Current issues in molecular biology. 2026 Jun 04;48(6):594. [Content Brief]
- [6]. Iyoda T, et al. Coadministration of the FNIII14 Peptide Synergistically Augments the Anti-Cancer Activity of Chemotherapeutic Drugs by Activating Pro-Apoptotic Bim. PloS one. 2016;11(9):e0162525. [Content Brief]
- [7]. Kato R, et al. A new type of antimetastatic peptide derived from fibronectin. Clin Cancer Res. 2002 Jul;8(7):2455-62. [Content Brief]
- [8]. Liu Z, et al. FNIII14 Peptide-Enriched Membrane Nanocarrier to Disrupt Stromal Barriers through Reversing CAFs for Augmenting Drug Penetration in Tumors. Nano letters. 2023 Nov 08;23(21):9963-9971. [Content Brief]
- [9]. Iyoda T, et al. Bioactive TNIIIA2 Sequence in Tenascin-C Is Responsible for Macrophage Foam Cell Transformation; Potential of FNIII14 Peptide Derived from Fibronectin in Suppression of Atherosclerotic Plaque Formation. International journal of molecular sciences. 2024 Feb 02;25(3):1825. [Content Brief]
- [10]. Kamiya S, et al. Fibronectin peptides derived from two distinct regions stimulate adipocyte differentiation by preventing fibronectin matrix assembly. Biochemistry. 2002 Mar 05;41(9):3270-7. [Content Brief]
Keywords
